New oral weight loss drug enters human testing

NCT ID NCT07239973

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tests an experimental weight loss pill called BGM0504 in 75 healthy and overweight or obese Chinese adults. Participants will receive either the drug or a placebo to check for side effects and measure weight changes over 8 weeks. The goal is to see if the drug is safe enough for further study.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
BGM0504 tablets
What this could lead to
If successful, this could lead to a new oral medication for weight management in overweight or obese individuals.
What could go wrong
This is an early Phase 1 trial with only 75 participants, focused on safety. It is too small and early to know if the drug works or is safe long-term.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • The First Affiliated Hospital of Yunnan University of Chinese Medicine

    RECRUITING

    Kunming, Yunnan, 650000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.